

SOUTHERN ONLINE BIO TECHNOLOGIES LTD



Date: August 09, 2022

To
The Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Ref: Scrip code: 532669

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that, the meeting of the Board of Directors of the Company held on Tuesday, August 09, 2022, commenced at 11:30 A.M and concluded at 04.15 P.M.

The Board inter-alia considered and approved the following:

1. Approved the unaudited standalone financial results of the Company for the quarter ended June 30, 2022. **(enclosed herewith)**
2. Took note of the Limited Review Report issued by M/s. Darapaneni & Co., Chartered Accountants, Statutory Auditors of the Company on the unaudited standalone financial results for the quarter ended June 30, 2022. **(enclosed herewith)**

You are requested to take the same on your record.

Thanking you
For Southern Online Bio Technologies Limited

R. Tibrewal



Rohit Tibrewal
Company Secretary

Encl: A/a.

CIN: L72900TG1998PLC030463

Registered Office: A3, 3rd Floor, Office Block, Samrat Complex, Saifabad, Hyderabad - 500 004. Telangana, India.
Phones: +91-40-23241999, +91-40-44341999, Fax: +91-40-23241444, email: cs@sol.net.in, website: www.sol.net.in
Unit - I : Survey No. 6 & 7, Samsthan Narayanapur (V&M), Yadadri Bhuvanagiri Dist., Telangana, Ph.: +91 8681 287575
Unit - II : Plot No. 45/A, APIIC-SEZ, Atchutapuram (V&M), Visakhapatnam Dist.-531011, Andhra Pradesh, India.
Corporate Office: Flat No. 602, 6th Floor, Swarna Jayanthi Complex, Beside Maitrivanam, Ameerpet, Hyderabad - 500 038.

SOUTHERN ONLINE BIO TECHNOLOGIES LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30 2022

Rs in lakhs

Particulars	Quarter ended			Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I Revenue from operations				
Sale of goods/Income from operations	81.48	70.60	57.74	248.42
Other operating revenues				
Total revenue from operations	81.48	70.60	57.74	248.42
II Other income	3.10	2.92	2.10	11.51
III Total income (I+II)	84.58	73.52	59.84	259.93
IV Expenses				
a) Cost of materials consumed	119.30	(0.00)	-	148.15
b) Purchases of stock- in-trade		-		
c) Changes in inventories of finished goods and work in progress	(119.40)	0.00	-	(148.15)
d) Employee benefits expenses	9.10	9.04	7.99	35.43
e) Finance costs	0.06	0.00	0.01	0.08
f) Depreciation and amortisation expense	5.81	3.19	6.42	21.88
g) Other expenses	61.37	56.23	36.90	179.57
Total expenses	76.25	68.46	51.32	236.96
V Profit/(loss) before tax (III-IV)	8.34	5.05	8.52	22.97
VI Tax expenses:				
a) Current tax	-	-	-	-
b) Deferred tax charge/(credit)	-	-	-	-
Total Tax Expense	-	-	-	-
VII Net Profit for the period (V-VI)	8.34	5.05	8.52	22.97
VIII Other comprehensive income(net of tax)				
a) (i) Items that will not be reclassified to profit or loss				
Remeasurements of the net defined benefit plans		1.40		(0.14)
b) Income tax relating to these items that will not be reclassified subsequently to profit or loss		-		-
Other comprehensive income/(loss) (net of tax)	-	1.40	-	(0.14)
IX Total comprehensive income/(loss) (VII+VIII)	8.34	6.46	8.52	22.83
X Paid-up Equity Share Capital (face value ₹ 10 each)	4,500.00	4,500.00	4,500.00	4,500.00
XI Other Equity	521.94	490.77	499.29	513.60
XII Net Worth	5,021.94	4,990.77	4,999.29	5,013.60
XIII Debenture Redemption reserve				
XIV Capital Redemption reserve				
XV Securities premium account				
XVI Paid-up debt Capital				
XVII Earnings per share (face value ₹ 10 each)				
a) Basic (₹)	0.02	0.01	0.02	0.05
b) Diluted (₹)	0.02	0.01	0.02	0.05



XVIII	Ratios				
a)	Debt Equity Ratio	0.72	0.66	0.24	0.66
b)	Debt Service Coverage Ratio	-	-	-	-
c)	Interest Service Coverage Ratio	139.85	5,052.79	926.05	286.00
d)	Current Ratio	4.15	12.80	8.04	12.80
e)	Long term debt to working capital	3.36	3.31	2.24	3.31
f)	Current liability ratio	0.09	0.02	0.06	0.02
g)	Total debts to total assets	0.43	0.39	0.19	0.39
h)	Bad debts to Account receivable ratio	-	-	-	-
i)	Debtors turnover	0.27	0.25	0.20	0.89
j)	Inventory turnover	0.27	0.25	0.20	0.89
k)	Operating margin (%)	0.06	0.03	0.11	0.05
l)	Net profit margin (%)	0.10	0.07	0.15	0.09

Notes

1. The above Financial results have been reviewed by the audit committee, approved by the Board of Directors in its meeting held on August 9, 2022 and reviewed by the Statutory auditors of the Company
2. Currently the Company operates in single segment namely 'Internet Service Provider Division' where as another segment i.e 'Bio Diesel Manufacturing' is not operational since last two years
3. The Financial results of the Company have been prepared in accordance with Indian Accounting Standards (IND AS) notified under the Companies (Indian Accounting Standards) Rules 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016
4. Previous period's figure have been re-grouped/re-arranged/re-casted wherever required in conformity with current period's presentation

For Southern Online Bio Technologies Limited

Dr Devaiah Pagidipati
Chairman and Managing Director
(DIN: 05147621)

Place: Hyderabad

Date: August 09, 2022





DARAPANENI & Co., CHARTERED ACCOUNTANTS

Flat No 1A, Rama Apartments, Plot No 84, Srinagar Colony, Hyderabad - 500073

Tel: 040-23735095, 23736487

E-mail: darapaneni1986@gmail.com

LIMITED REVIEW REPORT

Limited Review Report on Standalone Unaudited Quarterly Financial Results Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To the Board of Directors of Southern Online Bio Technologies Ltd

We have reviewed the accompanying statement of unaudited financial results of **M/s SOUTHERN ONLINE BIO TECHNOLOGIES LTD**, for the quarter ended 30th June 2022, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.


This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 09.08.2022

For Darapaneni & Co
Chartered Accountants
FRN.000685S



CA. SRC Murthy
Partner
M.No. 233010
UDIN: 22233010AOQJGQ5572